Skip Navigation


Annals of Oncology Advance Access originally published online on September 14, 2007
Annals of Oncology 2008 19(2):223-232; doi:10.1093/annonc/mdm352
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME/CE:
Take the course for this article:
 Annals of Oncology course: part 7 iss...
Right arrow All Versions of this Article:
19/2/223    most recent
mdm352v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Azambuja, E.
Right arrow Articles by Cardoso, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Azambuja, E.
Right arrow Articles by Cardoso, F.
Related Collections
Right arrow 2008 - Review Articles
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology. For Permissions, please email: journals.permissions@oxfordjournals.org

reviews

HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancer

E. Azambuja1,2,3, V. Durbecq1,2, D. D. Rosa1,2, M. Colozza4, D. Larsimont1,2, M. Piccart-Gebhart1,2 and F. Cardoso1,2,*

1 Departments of Medical Oncology and Translational Research Unit—Jules Bordet Institute, Brussels
2 L'Université Libre de Bruxelles (ULB), Brussels, Belgium
3 Ciências Médicas, Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
4 S.C. Oncologia Medica, Azienda Ospedaliera, San Sisto 06132 Perugia, Italy

* Correspondence to: Dr F. Cardoso, MD, Jules Bordet Institute, Boulevard de Waterloo, 125, 1000 Brussels, Belgium. Tel: +32-2-541-3082; Fax: +32-2-541-0858; E-mail: fatima.cardoso{at}bordet.be

Breast cancer (BC) is the most common cancer in women and it is incurable when metastases are diagnosed. Taxanes, namely docetaxel and paclitaxel, are effective chemotherapeutic agents in the metastatic, neoadjuvant and adjuvant settings. HER-2 overexpression/amplification is detected in 25–30% of BCs and confers aggressive tumor behavior as well as resistance to some systemic treatments; nevertheless, its association with response to taxane-based chemotherapy is still unclear, with conflicting results in both in vitro and in vivo preclinical studies. This review will address the impact of HER-2 overexpression/amplification in BC patients treated with taxanes. Prospective, randomized trials incorporating important biological hypotheses are either ongoing or just closed, and their results will hopefully help to shed more light on this issue.

Key words: breast cancer, ECD, HER-2 overexpression, taxane resistance, trastuzumab

Received for publication March 8, 2007. Revision received June 7, 2007. Accepted for publication June 8, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.